Concepedia
Statistics
Publications
9
Citations
855
H-Index
Active since
2004
Affiliations
National Cancer Institute(Current)
Virginia Commonwealth University
National Institutes of Health
National Institute of Neurological Disorders and Stroke
Center for Cancer Research
Tanyifor M. Tohnya is an author at National Cancer Institute specializing in pharmacology, cancer pharmacology, and oncology.
Publications per year
2004–2011
Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock et al. · Journal of Clinical Oncology · 2010 · 440 citations
Life Sciences, Oncology, Pharmacology +17
A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
D. Ross Camidge, Roy S. Herbst, Michael S. Gordon et al. · Clinical Cancer Research · 2010 · 169 citations
Pharmacy, Pharmacokinetics, Pharmacology +17
A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors
Howard A. Fine, Lyndon Kim, Paul S. Albert et al. · Clinical Cancer Research · 2007 · 66 citations
Medicine, Oncology, Pharmacology +17
Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer
William L. Dahut, Jeanny B. Aragon‐Ching, Sukyung Woo et al. · The Journal of Clinical Pharmacology · 2009 · 56 citations
Pharmacy, Pharmacokinetics, Pharmacology +16
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography–mass spectrometry
Tanyifor M. Tohnya, Kyunghwa Hwang, Erin R. Lepper et al. · Journal of Chromatography B · 2004 · 32 citations
Natural Sciences, Chemistry, Pharmacokinetics +11
1–5 of 9